According to the jury, comprised of Carine van den Brink, Geert-Jan Mulder, Ronald van der Geest, Christopher Allen and Martijn Hackman choosing a winner was a tough decision. The participating teams all had high quality pitches. In the end the winning team had the most convincing pitch and Q&A according to the jury.
Sniper Therapeutics is revolutionizing engineered T-cell therapies for solid tumors. The jury finds that the team is addressing a real need as their groundbreaking approach addresses one of the most critical challenges in this field: the inability of many T cells to effectively locate and destroy tumor cells. By leveraging novel biomarkers, Sniper Therapeutics enriches and selects T cells with superior tumor-killing capabilities, creating best-in-class therapies known as ‘Sniper’ T cell therapies.
Their first focus is on Diffuse Midline Glioma (DMG), a devastating pediatric brain tumor, with plans to expand their therapies to tackle a wide range of solid tumors. With strong scientific foundations, two proprietary innovations, and a highly experienced team led by Amber Wezenaar, Dr. Anne Rios and Saharla Ahmed, Sniper Therapeutics is set to make a transformative impact in oncology. Sniper Therapeutics originates from the Dream3DLab led by Dr. Anne Rios at the Princess Máxima Center for Pediatric Oncology in Utrecht and is affiliated with and supported by Oncode Institute.
“At Sniper Therapeutics we want to help cancer patients survive the impossible. Winning the Venture Challenge has brought us one step closer to this goal and will help us to develop best-in-class engineered T-cell therapies.”
- Amber Wezenaar, co-founder of Sniper Therapeutics
The Venture Challenge Fall started in October and today at the Dutch Life Sciences Conference Sniper Therapeutics takes home the €25.000 prize money to invest in their growth. Contact Amber Wezenaar for more information about Sniper Therapeutics.
The other highly-motivated participating teams were: VitalWear, Novya Biotech, Kingfisher, RadiGene and Supravision. As mentioned before, the jury sees great potential in all of these outstanding teams!
Participating in the Venture Challenge leads to a clear venture plan, as well as to investor-ready pitches. The LifeSciences@Work Venture Challenge is powered by Health~Holland | Top Sector Life Sciences & Health. The sponsors of the 25.000 euro prize: Loyens & Loeff and Pivot Park are detrimental to the success of the Venture Challenge.
Our specialised coaching focuses on developing your initial idea into a solid business during a series of boot camps and 1-on-1 coaching and mentoring sessions. Startup teams learn to identify key risks, analyse customer value propositions, develop a validation strategy, learn to build a venture plan and, ultimately, get connected to Life Sciences experts, investors and seasoned entrepreneurs. LifeSciences@Work: The national program for high potential Life Sciences start-up initiatives. We help scientists build their business. We offer activities designed for researchers with entrepreneurial aspirations as well as for life sciences startups.
Want to participate in the next venture challenge? Click here for more information and apply before 4 February 2025!